Acceptability of Depo-subQ in Uniject
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- FHI 360
- 入组人数
- 476
- 试验地点
- 2
- 主要终点
- Measure the acceptability of Depo-subQ in Uniject among DMPA IM family planning clients;
研究概览
简要总结
This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the introduction of this method.
详细描述
This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the introduction of this method.
A total of 560 participants will be enrolled in the study in the following groups:
360 participants (120 in Uganda and 240 in Senegal) who are current DMPA IM clients who seek re-injection of DMPA from either community health workers (CHWs) or clinic-based providers; and are 18-40 years of age; received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study [16].
Up to 100 participants (50 in Uganda and 50 in Senegal) current DMPA IM clients who meet the inclusion/exclusion criteria but do not want to receive the injection with Depo-subQ in Uniject and are willing to complete a short questionnaire
80 CHWs (40 in Uganda and 40 in Senegal) and 20 clinic-based providers (from Senegal only) who are trained to give Depo-subQ in Uniject as part of this study
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Age 18-40
- •In general good health (the participant verbally reports she feels well)
- •Using DMPA continuously for at least six months prior to enrollment in the study (i.e., had at least two previous injections)
- •Received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study at the study clinic or from a family planning provider involved in the study (Senegal only)
- •Received their most recent DMPA injection no more than 13 weeks prior to enrollment in the study from a family planning provider involved in the study (Uganda only)
- •Desires to be re-injected with DMPA
- •Willing to sign an informed consent document
- •Willing to provide contact information and be interviewed three months after enrollment.
排除标准
- 未提供
结局指标
主要结局
Measure the acceptability of Depo-subQ in Uniject among DMPA IM family planning clients;
时间窗: 1 year
percent of participants who declare they would select Depo-subQ in Uniject for their next injection if this drug product was available at three months with a 95% confidence interval per country
2) Measure the acceptability of Depo-subQ in Uniject among family planning providers (both clinic-based and CHWs);
时间窗: 1 year
key themes will be identified from interview transcripts to summarize family planning providers' (clinic-based and CHWs) acceptability of Depo-subQ in Uniject and preference for administering Depo-subQ in Uniject relative to the typical DMPA intramuscular injection by county
Assess family planning providers' (clinic-based and CHWs) training materials.
时间窗: 1 year
descriptive analyses (e.g., frequencies and means) of responses for quantitative questions and summaries providers' qualitative responses to open-ended questions from the post-training evaluation for each country
次要结局
- 1) To qualitatively compare acceptability of Depo-subQ in Uniject among the two types of family planning providers-clinic-based and CHWs (Senegal only)(1 year)
- 2) To assess the safety of participants who receive Depo-subQ in Uniject during the study(1 year)